Show simple item record

dc.contributor.authorSolda, F
dc.contributor.authorWharram, B
dc.contributor.authorDe Ieso, PB
dc.contributor.authorBonner, J
dc.contributor.authorAshley, S
dc.contributor.authorBrada, M
dc.date.accessioned2018-08-03T14:45:57Z
dc.date.issued2013-11
dc.identifier2
dc.identifier.citationRADIOTHERAPY AND ONCOLOGY, 2013, 109 pp. 330 - 334
dc.identifier.issn0167-8140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2265
dc.identifier.doi10.1016/j.radonc.2013.10.006
dc.description.abstractPurpose: To assess long term efficacy of fractionated stereotactic radiotherapy (fSRT) in the treatment of benign intracranial meningiomas. Materials and methods: Retrospective study of 222 patients with histologically confirmed (58%) and unverified presumed (42%) grade I intracranial meningioma treated with fSRT in a single institution to doses of 50-55 Gy in 30-33 fractions. Results: At a median follow-up of 43 months (range 3-144) the 5 and 10 years local control (LC) were 93% and 86%. Patients with tumors involving the optic nerve (42 patients) and patients with cavernous sinus/parasellar region meningiomas (78 patients) had 5 and 10 years LC of 100%. The 5 and 10 years survival probabilities were 93% and 84%. On multivariate analysis gender and tumor site were independent predictors of LC. Worsening of pre-existing cranial nerve deficit occurred in 8 (3.5%) and onset of new deficit in 1(0.5%) patient. Two patients with optic nerve sheath meningioma (1%) developed radiation retinopathy. There were no cases of radiation necrosis or second brain tumors. Conclusion: fSRT achieves excellent medium and long term tumor control with minimal morbidity particularly in patients with benign meningiomas involving the parasellar region and the optic nerves and questions the role of other treatment modalities for tumors at these locations. (C) 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 330-334
dc.format.extent330 - 334
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER IRELAND LTD
dc.titleLong-term efficacy of fractionated radiotherapy for benign meningiomas
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.radonc.2013.10.006
rioxxterms.licenseref.startdate2013-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRADIOTHERAPY AND ONCOLOGY
pubs.notesaffiliation: Brada, M (Reprint Author), LOC Leaders Oncol Care, 95 Harley St, London W1G 6AF, England. Solda, Francesca; Wharram, Beverley; De Ieso, Paul B.; Bonner, Jacob; Ashley, Sue; Brada, Michael, Royal Marsden NHS Fdn Trust, Neurooncol Unit, London, England. Brada, Michael, Inst Canc Res, Acad Unit Radiotherapy & Oncol, London SW3 6JB, England. keywords: Skull base; Intracranial; Meningioma; Fractionated stereotactic radiotherapy keywords-plus: SKULL BASE MENINGIOMAS; CAVERNOUS SINUS MENINGIOMAS; STEREOTACTIC CONFORMAL RADIOTHERAPY; GAMMA-KNIFE RADIOSURGERY; LOCAL TUMOR-CONTROL; INTRACRANIAL MENINGIOMAS; RADIATION RETINOPATHY; MANAGEMENT; IRRADIATION; EXPERIENCE research-areas: Oncology; Radiology, Nuclear Medicine & Medical Imaging web-of-science-categories: Oncology; Radiology, Nuclear Medicine & Medical Imaging author-email: [email protected] funding-acknowledgement: Neuro-oncology Research Fund of the Royal Marsden NHS Foundation Trust; Cancer Research UK; Royal Marsden NHS Foundation Trust; NHS Executive funding-text: The work of the Neuro-oncology Unit was supported by the Neuro-oncology Research Fund of the Royal Marsden NHS Foundation Trust. The Neuro-oncology Unit also received funding from the Cancer Research UK and the Royal Marsden NHS Foundation Trust. UK hospitals receive a proportion of their funding from the NHS Executive; the views expressed are those of the authors and not necessarily those of the NHS Executive. number-of-cited-references: 44 times-cited: 18 usage-count-last-180-days: 0 usage-count-since-2013: 5 journal-iso: Radiother. Oncol. doc-delivery-number: 280HS unique-id: ISI:000329019900026 da: 2018-08-03
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume109
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record